GENFIT and LabCorp Sign Exclusive Agreement to Commercialize a Novel Diagnostic Test for Liver Disease

NEXT STORY
Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA
PREV STORY
Basilea beginnt Phase-1/2-Studie FIDES-03 mit Derazantinib bei Patienten mit Magenkrebs
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ventilators Market Worth $7.72 billion by 2027- Exclusive Report by Meticulous Research® Covering Emerging Growth Factors, Latest Trends and Forecasts, and Pre and Post COVID-19 Estimates

author_avatar
NASDAQ Market News

Basilea gibt positive Topline-Ergebnisse aus Phase-2-Studie FIDES-01 mit Derazantinib bei Patienten mit Gallengangkrebs (iCCA) und Fusionen des FGFR2-Gens bekannt

author_avatar
NASDAQ Market News

Affimed Presents Data on First-in-Class BCMA-Targeting Immune Cell Engager AFM26 at ASCO Annual Meeting 2017

Heidelberg, Germany, June 6, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical ...

author_avatar
NASDAQ Market News